ID: ALA3337658

Max Phase: Preclinical

Molecular Formula: C19H18ClN3O7

Molecular Weight: 435.82

Molecule Type: Small molecule

Representations

Canonical SMILES:  N[C@@H](Cc1cc(Cl)c(NC(=O)c2cccc([N+](=O)[O-])c2)cc1CCC(=O)O)C(=O)O

Standard InChI:  InChI=1S/C19H18ClN3O7/c20-14-7-12(8-15(21)19(27)28)10(4-5-17(24)25)9-16(14)22-18(26)11-2-1-3-13(6-11)23(29)30/h1-3,6-7,9,15H,4-5,8,21H2,(H,22,26)(H,24,25)(H,27,28)/t15-/m0/s1

Standard InChI Key:  ZPNIWXWAMNGDAU-HNNXBMFYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 435.82

Molecular Weight (Monoisotopic): 435.0833

AlogP: 2.47

#Rotatable Bonds: 9

Polar Surface Area: 172.86

Molecular Species: ZWITTERION

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.60

CX Basic pKa: 9.42

CX LogP: 0.45

CX LogD: -2.76

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.34

Np Likeness Score: -0.73

References

1. Sköld N, Nielsen B, Olsen J, Han L, Olsen L, Madsen U, Kristensen JL, Pickering DS, Johansen TN..  (2014)  Design, synthesis and in vitro pharmacology of GluK1 and GluK3 antagonists. Studies towards the design of subtype-selective antagonists through 2-carboxyethyl-phenylalanines with substituents interacting with non-conserved residues in the GluK binding sites.,  22  (19): [PMID:25172149] [10.1016/j.bmc.2014.07.045]

Source

Source(1):

• Scientific Literature